🚀 VC round data is live in beta, check it out!
Mural Oncology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mural Oncology and similar public comparables like Eli Lilly, Johnson & Johnson, AbbVie, Roche and more.
Mural Oncology Overview
About Mural Oncology
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
Founded
2017
HQ
Employees
116
Website
Sectors
Financials (FY)
Market Cap
—
Mural Oncology Stock Performance
Mural Oncology has current market cap of —.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| — | — | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMural Oncology Valuation Multiples
Mural Oncology Financial Valuation Multiples
As of March 11, 2026, Mural Oncology has market cap of —.
Equity research analysts estimate Mural Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 |
|---|
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mural Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mural Oncology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Eli Lilly | XXX | XXX | XXX | XXX | XXX | XXX |
| Johnson & Johnson | XXX | XXX | XXX | XXX | XXX | XXX |
| AbbVie | XXX | XXX | XXX | XXX | XXX | XXX |
| Roche | XXX | XXX | XXX | XXX | XXX | XXX |
| Novartis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mural Oncology M&A Activity
Mural Oncology acquired XXX companies to date.
Last acquisition by Mural Oncology was on XXXXXXXX, XXXXX. Mural Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mural Oncology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMural Oncology Investment Activity
Mural Oncology invested in XXX companies to date.
Mural Oncology made its latest investment on XXXXXXXX, XXXXX. Mural Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mural Oncology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mural Oncology
| When was Mural Oncology founded? | Mural Oncology was founded in 2017. |
| Where is Mural Oncology headquartered? | Mural Oncology is headquartered in Ireland. |
| How many employees does Mural Oncology have? | As of today, Mural Oncology has over 116 employees. |
| Is Mural Oncology publicly listed? | Yes, Mural Oncology is a public company listed on Nasdaq. |
| What is the stock symbol of Mural Oncology? | Mural Oncology trades under MURA ticker. |
| When did Mural Oncology go public? | Mural Oncology went public in 2023. |
| Who are competitors of Mural Oncology? | Mural Oncology main competitors are Eli Lilly, Johnson & Johnson, AbbVie, Roche. |
| Is Mural Oncology profitable? | No, Mural Oncology is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.